Lublin FD, Reingold SC, Cohen JA, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014;83(3):278–86.

Article  Google Scholar 

Miller DH, Weinshenker BG, Filippi M, et al. Differential diagnosis of suspected multiple sclerosis: a consensus approach. Mult Scler. 2008;14(9):1157–74.

Article  CAS  Google Scholar 

Lassmann H, van Horssen J, Mahad D. Progressive multiple sclerosis: pathology and pathogenesis. Nat Rev Neurol. 2012;8(11):647–56.

Article  CAS  Google Scholar 

Giovannoni G, Popescu V, Wuerfel J, et al. Smouldering multiple sclerosis: the “real MS.” Ther Adv Neurol Disord. 2022;15:17562864211066752.

Article  Google Scholar 

Kappos L, Butzkueven H, Wiendl H, et al. Greater sensitivity to multiple sclerosis disability worsening and progression events using a roving versus a fixed reference value in a prospective cohort study. Mult Scler. 2018;24(7):963–73.

Article  Google Scholar 

Lorscheider J, Benkert P, Schädelin S, et al., Disability progression unrelated to relapses in relapsing-remitting multiple sclerosis: insights from the Swiss multiple sclerosis cohort study. ECTRIMS Online Library. 2019. 279536(273).

von Wyl V, Benkert P, Lorscheider J et al. Progression independent of relapse activity (PIRA) in relapsing-remitting multiple sclerosis patients on first-line immunomodulatory treatment with fingolimod vs. platform injectables. In: ECTRIMS, 2019. Stockholm.

Graf J, Leussink VI, Soncin G, et al. Relapse-independent multiple sclerosis progression under natalizumab. Brain Commun. 2021;3(4):fcab229.

Article  Google Scholar 

Lublin FD, Häring DA, Ganjgahi H, et al. How patients with multiple sclerosis acquire disability. Brain. 2022.

Portaccio E, Bellinvia A, Fonderico M, et al. Progression is independent of relapse activity in early multiple sclerosis: a real-life cohort study. Brain. 2022;145(8):2796–805.

Article  Google Scholar 

Kappos L, Wolinsky JS, Giovannoni G, et al. Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials. JAMA Neurol. 2020;77(9):1132–40.

Article  Google Scholar 

European Medicines Agency Science Medicines Health. (2015, March 26). Guideline on clinical investigation of medicinal products for the treatment of Multiple Sclerosis. European Medicines Agency Science Medicines Health. Retrieved September 18, 2022, from https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-treatment-multiple-sclerosis_en-0.pdf.

Barzegar M, Najdaghi S, Afshari-Safavi A, et al. Early predictors of conversion to secondary progressive multiple sclerosis. Mult Scler Relat Disord. 2021;54: 103115.

Article  Google Scholar 

Tremlett H, Yinshan Z, Devonshire V. Natural history of secondary-progressive multiple sclerosis. Mult Scler. 2008;14(3):314–24.

Article  Google Scholar 

Abdelhak A, Weber MS, Tumani H. Primary progressive multiple sclerosis: putting together the puzzle. Front Neurol. 2017;8:234.

Article  Google Scholar 

Rice CM, Cottrell D, Wilkins A, et al. Primary progressive multiple sclerosis: progress and challenges. J Neurol Neurosurg Psychiatry. 2013;84(10):1100–6.

Article  Google Scholar 

Butzkueven H, Chapman J, Cristiano E, et al. MSBase: an international, online registry and platform for collaborative outcomes research in multiple sclerosis. Mult Scler. 2006;12(6):769–74.

Article  CAS  Google Scholar 

Lorscheider J, Buzzard K, Jokubaitis V, et al. Defining secondary progressive multiple sclerosis. Brain. 2016;139(Pt 9):2395–405.

Article  Google Scholar 

Kopp TI, Bramow S, Illes Z, et al. Application of definitions for conversion to secondary progressive MS in a Danish nationwide population. Mult Scler Relat Disord. 2021;56: 103319.

Article  Google Scholar 

Boyko A, Therapontos C, Horakova D, et al. Approaches and challenges in the diagnosis and management of secondary progressive multiple sclerosis: a Central Eastern European perspective from healthcare professionals. Mult Scler Relat Disord. 2021;50: 102778.

Article  Google Scholar 

Katz Sand I, Krieger S, Farrell C, et al. Diagnostic uncertainty during the transition to secondary progressive multiple sclerosis. Mult Scler. 2014;20(12):1654–7.

Article  Google Scholar 

Rojas JI, Patrucco L, Alonso R, et al. Diagnostic uncertainty during the transition to secondary progressive multiple sclerosis: multicenter study in Argentina. Mult Scler. 2021;27(4):579–84.

Article  Google Scholar 

Frischer JM, Bramow S, Dal-Bianco A, et al. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain. 2009;132(Pt 5):1175–89.

Article  Google Scholar 

Lassmann H. Pathogenic mechanisms associated with different clinical courses of multiple sclerosis. Front Immunol. 2018;9:3116.

Article  CAS  Google Scholar 

Williams T, Zetterberg H, Chataway J. Neurofilaments in progressive multiple sclerosis: a systematic review. J Neurol. 2021;268(9):3212–22.

Article  Google Scholar 

Invernizzi P, Bertolasi L, Bianchi MR, et al. Prognostic value of multimodal evoked potentials in multiple sclerosis: the EP score. J Neurol. 2011;258(11):1933–9.

Article  Google Scholar 

Leocani L, Rovaris M, Boneschi FM, et al. Multimodal evoked potentials to assess the evolution of multiple sclerosis: a longitudinal study. J Neurol Neurosurg Psychiatry. 2006;77(9):1030–5.

Article  CAS  Google Scholar 

Margaritella N, Mendozzi L, Garegnani M, et al. Sensory evoked potentials to predict short-term progression of disability in multiple sclerosis. Neurol Sci. 2012;33(4):887–92.

Article  CAS  Google Scholar 

Schlaeger R, D’Souza M, Schindler C, et al. Prediction of MS disability by multimodal evoked potentials: investigation during relapse or in the relapse-free interval? Clin Neurophysiol. 2014;125(9):1889–92.

Article  CAS  Google Scholar 

Abalo-Lojo JM, Limeres CC, Gómez MA, et al. Retinal nerve fiber layer thickness, brain atrophy, and disability in multiple sclerosis patients. J Neuroophthalmol. 2014;34(1):23–8.

Article  Google Scholar 

Martinez-Lapiscina EH, Arnow S, Wilson JA, et al. Retinal thickness measured with optical coherence tomography and risk of disability worsening in multiple sclerosis: a cohort study. Lancet Neurol. 2016;15(6):574–84.

Article  Google Scholar 

Ratchford JN, Saidha S, Sotirchos ES, et al. Active MS is associated with accelerated retinal ganglion cell/inner plexiform layer thinning. Neurology. 2013;80(1):47–54.

Article  Google Scholar 

Valsasina P, Rocca MA, Horsfield MA, et al. Regional cervical cord atrophy and disability in multiple sclerosis: a voxel-based analysis. Radiology. 2013;266(3):853–61.

Article  Google Scholar 

Eshaghi A, Prados F, Brownlee WJ, et al. Deep gray matter volume loss drives disability worsening in multiple sclerosis. Ann Neurol. 2018;83(2):210–22.

Article  CAS  Google Scholar 

Cree BAC, Hollenbach JA, Bove R, et al. Silent progression in disease activity-free relapsing multiple sclerosis. Ann Neurol. 2019;85(5):653–66.

Article  Google Scholar 

Gil-Perotin S, Alcalá C, Pérez-Miralles FC, et al. Silent progression or bout onset progressive multiple sclerosis? Ann Neurol. 2019;86(3):472.

Article  Google Scholar 

Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33(11):1444–52.

Article  CAS  Google Scholar 

Amato MP, Prestipino E, Bellinvia A. Identifying risk factors for cognitive issues in multiple sclerosis. Expert Rev Neurother. 2019;19(4):333–47.

Article  CAS  Google Scholar 

Zipoli V, Goretti B, Hakiki B, et al. Cognitive impairment predicts conversion to multiple sclerosis in clinically isolated syndromes. Mult Scler. 2010;16(1):62–7.

Article  Google Scholar 

European Medicines Agency Science Medicines Health. (2020, February 26). Qualification opinion on Multiple Sclerosis Clinical Outcome Assessment (MSCOA). European Medicines Agency Science Medicines Health. Retrieved September 18, 2022, from https://www.ema.europa.eu/en/documents/other/qualification-opinion-multiple-sclerosisclinical-outcome-assessment-mscoa_en.pdf.

Polman CH, Rudick RA. The multiple sclerosis functional composite: a clinically meaningful measure of disability. Neurology. 2010;74(Suppl 3):S8-15.

Article  Google Scholar 

Wolinsky JS, Arnold DL, Brochet B, et al. Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2020;19(12):998–1009.

Article  CAS  Google Scholar 

Ziemssen T, Giovannoni G, Alvarez E, et al. Multiple sclerosis progression discussion tool usability and usefulness in clinical practice: cross-sectional, web-based survey. J Med Internet Res. 2021;23(10): e29558.

Article  Google Scholar 

Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet. 1998;352(9139):1498–504.

Randomized controlled trial of interferon- beta-1a in secondary progressive MS: clinical results. Neurology. 2001;56(11):1496–504.

Freedman MS, Brod S, Singer BA, et al. Clinical and MRI efficacy of sc IFN β-1a tiw in patients with relapsing MS appearing to transition to secondary progressive MS: post hoc analyses of PRISMS and SPECTRIMS. J Neurol. 2020;267(1):64–75.

Article  CAS  Google Scholar 

Plosker GL. Interferon-β-1b: a review of its use in multiple sclerosis. CNS Drugs. 2011;25(1):67–88.

Article  CAS  Google Scholar 

Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS. Lancet. 1998;352(9139):1491–7.

Panitch H, Miller A, Paty D, et al. Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study. Neurology. 2004;63(10):1788–95.

Article  Google Scholar 

Kappos L, Li DK, Stüve O, et al. Safety and efficacy of siponimod (BAF312) in patients with relapsing-remitting multiple sclerosis: dose-blinded, randomized extension of the phase 2 BOLD study. JAMA Neurol. 2016;73(9):1089–98.

Article  Google Scholar 

Selmaj K, Li DK, Hartung HP, et al. Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study. Lancet Neurol. 2013;12(8):756–67.

Article  CAS  Google Scholar 

Hartung HP, Gonsette R, König N, et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet. 2002;360(9350):2018–25.

Article  Google Scholar 

Hauser SL, Bar-Or A, Comi G, et al. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med. 2017;376(3):221–34.

Article  CAS  Google Scholar 

Montalban X, Hauser SL, Kappos L, et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med. 2017;376(3):209–20.